Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
559
datasets available to search
ShareScore release 0.9.0
Dataset results
559 results for “Cancer metabolism”
Effect of Metformin on Breast Cancer Metabolism
ClinicalTrials.gov study NCT01266486. IPD Sharing: Not stated. Countries: 1. Publications: 3.
To Investigate the Role of Gut Microbiome in ADT Related Metabolic Changes in Prostate Cancer Patients
ClinicalTrials.gov study NCT04687709. IPD Sharing: NO. Countries: 1. Publications: 27.
Assessing the Changes in Markers of Calcium Vitamin Metabolism of for Breast Cancer Adjuvant (CALCIOBS)
ClinicalTrials.gov study NCT03249389. IPD Sharing: NO. Countries: 1. Publications: 0.
Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling
ClinicalTrials.gov study NCT02083692. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Metabolism Imaging-genomics for Predicting the Surgical Outcomes of Colorectal Cancer
ClinicalTrials.gov study NCT06614660. IPD Sharing: UNDECIDED. Countries: 1. Publications: 3.
Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity
ClinicalTrials.gov study NCT04717050. IPD Sharing: YES. Countries: 1. Publications: 0.
Physical Activity Targeting Metabolic Syndrome for Prevention of Breast Cancer in SAI Women
ClinicalTrials.gov study NCT06827704. IPD Sharing: NO. Countries: 1. Publications: 7.
Omentectomy for Metabolic Syndrome in Gastric Cancer Patients
ClinicalTrials.gov study NCT02641925. IPD Sharing: YES. Countries: 1. Publications: 7.
Arginine Feeding: a Novel Strategy to Improve Protein Metabolism in Cancer and the Response to Surgery
ClinicalTrials.gov study NCT00497380. IPD Sharing: Not stated. Countries: 1. Publications: 1.
PharmacoKINEtics of TAMoxifen and Its Metabolites in Breast Cancer Patients: the Influence of a Dose Increase in Phenotypic Poor Metabolizers of CYP2D6 (KINETAM)
ClinicalTrials.gov study NCT01192308. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Correlating the Tumoral Metabolic Progression Index to Patient's Outcome in Advanced Colorectal Cancer
ClinicalTrials.gov study NCT01591590. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Data for: Link between glucose metabolism and EMT drives triple negative breast cancer migratory heterogeneity
Open the record for dataset details and reuse information.
Metabolic syndrome and risk of lung cancer: An analysis of Korean National Health Insurance Corporation database
<p>Introduction: Metabolic syndrome is known to increase the risk of several cancers. However, the association between lung cancer and metabolic syndrome remains unclear. Thus, we investigated the impact of metabolic syndrome on the incidence of lung cancer.</p> <p>Methods: This study enrolled participants in a health screening program provided by the Korean National Health Insurance Service between January 2009 and December 2012. The incidence of lung cancer was observed until December 2016. We analyzed the risk of lung cancer according to the presence of metabolic syndrome, metabolic syndrome components, and number of metabolic syndrome components.</p> <p>Results: During the study, 45,635 new cases of lung cancer were recorded among 9,586,753 participants. The presence of metabolic syndrome and all its components was positively associated with the risk of lung cancer in males after multivariate adjustment (hazard ratio (HR) of metabolic syndrome 1.15, 95% confidence interval (CI) = 1.12–1.18). The risk of lung cancer increased with the number of components present. The effect of metabolic syndrome on the increasing risk of lung cancer is may be higher in underweight male ever smokers than in other participants.</p> <p>Conclusion: Metabolic syndrome was associated with an increased risk of lung cancer in males. Moreover, the higher the number of metabolic syndrome components, the higher the risk of lung cancer.</p>
Data from: Endocrine and metabolic disorders in survivors of childhood cancers and health-related quality of life and physical activity
Context: Childhood cancer survivors experience chronic health conditions that impact health related quality of life (HRQOL) and participation in optimal physical activity. Objective: The study aimed to determine independent effects of endocrine and metabolic disorders on HRQOL and physical activity. Design, Setting, and Patients: Retrospective cohort with longitudinal follow-up of survivors of childhood cancer enrolled in the North American Childhood Cancer Survivor Study. Main Outcome Measures: Medical Outcomes Short Form-36 estimated HRQOL while participation in physical activity was dichotomized as meeting or not meeting recommendations from the Center for Disease Control and Prevention. Log binomial regression evaluated the association of each endocrine/metabolic disorder with HRQOL scales and physical activity. Results: Of 7,287 survivors, median age 32 years (18-54) at their last follow-up survey, 4,884 (67%) reported one or more endocrine/metabolic disorders. Survivors with either disorder were significantly more likely to be male, older, received radiation treatment, and experience other chronic health conditions. After controlling for covariates, survivors with any endocrine/metabolic disorder were more likely to report poor physical function risk ratio ([RR] 1.25; 95% confidence interval [CI] 1.05-1.48), increased bodily pain (RR 1.27; CI 1.12-1.44), poor general health (RR 1.49; CI 1.32-1.68) and lower vitality (RR 1.21; CI 1.09-1.34) compared to survivors without. The likelihood of meeting recommended physical activity was lower among survivors with growth disorders (RR 0.90; CI=0.83-0.97), osteoporosis (RR 0.87; CI=0.76-0.99), and overweight/obesity (RR 0.92; CI 0.88-0.96). Conclusion: Endocrine and metabolic disorders are independently associated with poor HRQOL and sub-optimal physical activity among childhood cancer survivors.
Data from: Importance of metabolic rate to the relationship between the number of genes in a functional category and body size in Peto's paradox for cancer
Elucidation of tumour suppression mechanisms is a major challenge in cancer biology. Therefore, Peto's paradox, or low cancer incidence in large animals, has attracted focus. According to the gene-abundance hypothesis, which considers the increase/decrease in cancer-related genes with body size, researchers evaluated the associations between gene abundance and body size. However, previous studies only focused on a few specific gene functions and have ignored the alternative hypothesis (metabolic rate hypothesis): in this hypothesis, the cellular metabolic rate and subsequent oxidative stress decreases with increasing body size. In this study, we have elected to explore the gene-abundance hypothesis taking into account the metabolic rate hypothesis. Thus, we comprehensively investigated the correlation between the number of genes in various functional categories and body size while at the same time correcting for the mass-specific metabolic rate (Bc). A number of gene functions that correlated with body size were initially identified, but they were found to be artefactual due to the decrease in Bc with increasing body size. By contrast, immune system-related genes were found to increase with increasing body size when the correlation included this correction for Bc. These findings support the gene-abundance hypothesis and emphasize the importance of also taking into account the metabolic rate when evaluating gene abundance–body size relationships. This finding may be useful for understanding cancer evolution and tumour suppression mechanisms as well as for determining cancer-related genes and functions.
Identification of breast cancer subgroups and immune characterization based on glutamine metabolism-related genes
Open the record for dataset details and reuse information.
Metabolic Sodium MRI to Assess Early Response of Breast Cancer to Neoadjuvant Chemotherapy
ClinicalTrials.gov study NCT03750240. IPD Sharing: Not stated. Countries: 1. Publications: 0.
18F-FDG Metabolism Imaging Monitoring Non-small Cell Lung Cancer Curative Effect of Chemotherapy Multicenter Clinical Study
ClinicalTrials.gov study NCT02938546. IPD Sharing: UNDECIDED. Countries: 0. Publications: 13.
Dietary Patterns and Health Outcomes (Cardiovascular, Metabolic, Endocrine, Neurological, Skeletal Muscular, Cancer)
ClinicalTrials.gov study NCT03328546. IPD Sharing: NO. Countries: 0. Publications: 10.
A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine
ClinicalTrials.gov study NCT01992016. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.